Persistent organic pollutants and risk of cutaneous malignant melanoma among women

Maryam Darvishian1 | Parveen Bhatti1 | Éric Gaudreau2 | Zenaida Abanto1 | Charles Choi3 | Richard P. Gallagher1,4 | John J. Spinelli5 | Tim K. Lee1,4

1Cancer Control Research Program, BC Cancer, Vancouver, British Columbia, Canada
2Centre de Toxicologie du Québec (CTQ), Institut National de Santé Publique du Québec (INSPQ), Québec, Canada
3Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
4Department of Dermatology and Skin Sciences, University of British Columbia, Vancouver, British Columbia, Canada
5School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada

Correspondence
Maryam Darvishian, BC Cancer Research Centre, 675 W 10th Avenue, Vancouver, BC V5Z 1L3, Canada.
Email: mdarvishian@bccrc.ca

Funding information
Canadian Institutes of Health Research (CIHR), Grant/Award Number: MOP-102613

Abstract

Background: Despite the increasing trend of cutaneous malignant melanoma (CMM) incidence in Canada, especially among females, few risk factors other than ultraviolet radiation exposure, have been identified.

Aim: We conducted a case–control study of 406 CMM cases and 181 controls to evaluate the potential impact of body burdens of various persistent organic pollutants on CMM risk.

Methods: Detailed data on potential confounding factors, including lifetime repeated sun exposure and skin reaction to repeated sun exposure, were collected. Gas chromatography tandem mass spectrometry was used to assay plasma levels of 14 polychlorinated biphenyl (PCB) congeners and 11 organochlorine (OC) pesticides among cases and controls.

Results: Statistically significant trends of increased CMM risk were observed with increasing plasma concentrations of multiple PCB congeners, including PCBs 138, 153, 170, 180, 183 and 187. For example, compared to lowest plasma concentration quartile of PCB-138, the second, third and fourth quartiles were associated with 1.7 (95% CI: 0.9–2.9), 2.3 (95% CI: 1.3–4.1) and 2.4 (95% CI: 1.3–4.5) -fold increased risks of CMM, respectively. Similarly, increasing plasma concentrations of several OC pesticides (i.e., β-HCH, HCB, Mirex, oxychlordane and trans-Nonachlor) showed statistically significant trends with increased CMM, respectively. Similarly, increasing plasma concentrations of several OC pesticides (i.e., β-HCH, HCB, Mirex, oxychlordane and trans-Nonachlor) showed statistically significant trends with increased CMM, respectively. For example, compared to lowest plasma concentration quartile of β-HCH, the second, third and fourth quartiles were associated with 1.3 (95% CI: 0.7–2.3), 2.1 (95% CI: 1.2–3.7) and 2.3 (95% CI: 1.2–4.4) -fold increased risks of CMM, respectively.

Conclusion: Plasma levels of several persistent organic pollutants were highly correlated, suggesting that observed associations were not necessarily independent of each other. Given the highly correlated nature of exposure to PCB and OC analytes, sophisticated analyses that consider complex mixtures should be considered in future studies.

Keywords
melanoma, organochlorine pesticides, persistent organic pollutants, polychlorinated biphenyls, skin cancer
1 | INTRODUCTION

As in other parts of the world, there has been an increasing trend of cutaneous malignant melanoma (CMM) incidence in Canada. Since 1994, Canadian females have the second highest annual percent change in age-standardize incidence rate of melanoma over other cancers.1,2 Despite the increasing incidence, few risk factors, other than ultraviolet radiation exposure, have been identified.3

Polychlorinated biphenyls (PCBs) are a class of persistent organic pollutant (POP; i.e., compounds that bio-accumulate in the environment, animals and humans and can still be detected in the general population despite their use being banned decades ago) and have been classified as known human carcinogens by the International Agency for Research on Cancer (IARC).4–6 This was primarily based on evidence of increased melanoma risk among occupationally exposed individuals; however, more recently conducted meta-analyses, that primarily include highly exposed occupational groups, do not confirm IARC’s classification.7,8 Few studies of organochlorine (OC) pesticides, another class of POP, and CMM risk have also been conducted and, as with PCBs, the primary focus has been on occupational exposures. For example, in the Agricultural Health Study (AHS), toxaphene exposure, as assessed via questionnaire, was found to be associated with increased CMM risk, but this was not replicated in the AHS after additional years of follow-up.9,10

To assess the potential associations of PCB and OC pesticide exposures with risk of CMM in the general population, we previously conducted a preliminary population-based case–control study in BC.4 Comparing 80 CMM cases to 310 controls, we observed strong associations between plasma levels of various PCB congeners and OC pesticides and risk of CMM.4 We have now followed-up these findings with another study that includes a much larger number of cases. In addition, the study focuses on women given the steeper increases in CMM incidence observed in this group.

2 | METHODS

2.1 | Study population

The protocol for this investigation was approved by the Research Ethics Board of the University of British Columbia and the BC Cancer Agency.

Between July 2011 and January 2013, females aged 20–79 with CMM, were identified through the population-based BC Cancer Registry. A total of 703 cases were successfully contacted by telephone (up to three contact attempts were made), with 241 (34%) refusing to participate, leaving 462 (66%) that consented to participate in the study (Figure 1).

From December 2012 to May 2014, 2078 cancer-free controls, frequency matched to cases on age and residential district, were randomly selected from the consolidation file of the British Columbia Ministry of Health, which contains identifying information on all participants in the population-based health insurance plan. A total of 778 were successfully contacted by telephone, with 526 (67%) refusing to participate, leaving 252 (32%) that consented to participate in the study (Figure 1).
2.2 Data and blood sample collection

All study participants were asked to complete a computer-assisted telephone interview (CATI) to provide information on sun exposure, medical history, lifestyle factors, family history of melanoma, occupational history, and residential history. Participants were also asked to provide a whole blood sample, which was collected in EDTA tubes at a community laboratory and shipped, on ice, to BC Cancer within 24 h for collection and processing. A volume of 2 ml of plasma was separated from whole blood by centrifugation, transferred to vials with Teflon stoppers and frozen at –80°C.

2.3 PCB and OC pesticide assays

De-identified plasma samples were shipped in random batches of cases and controls to the Centre de Toxicologie du Québec (CTQ), Institut National de Santé Publique du Québec (INSPQ) for assay. Laboratory staff were blinded to case-control status. Fourteen PCB congeners (IUPAC nos. 28, 52, 99, 101, 105, 118, 128, 138, 153, 156, 170, 180, 183 and 187) and 11 OC pesticides (aldrin, β-hexachlorocyclohexane (β-HCH), α-chlordane, γ-chlordane, cis-Nonachlor, trans-Nonachlor, p,p′-DDT, p,p′-DDE, hexachlorobenzene (HCB), mirex, and oxychlordane), which were selected based on observations in the preliminary study,4,11 were measured using the gas chromatography-mass spectrometry (GC-MS) where the analytical method was described in Fisher et al.12 The limit of detection (LOD) varied from 0.01 to 0.3 μg/L for PCBs and varied from 0.005 to 0.09 μg/L for OCs (Table 1). Concentrations below the LOD were assigned a value of the LOD divided by √2.4,13

Using enzymatic methods, free cholesterol (FC), total cholesterol (TC), triglycerides (TG), and phospholipids (PL) were measured in each plasma sample.6 Total lipid concentration was calculated using the

---

### Table 1: Number of samples measured above limit of detection

| PCB congeners/pesticide analytes | LOD (μg/L) | Cases (n = 406) | Controls (n = 181) |
|--------------------------------|-----------|----------------|-------------------|
|                                | N         | %              | N                | %         | Median a(μg/kg of lipids) |
| **PCB congeners**              |           |                |                  |            |
| 28 a                           | 0.05      | 13 3.2%        | 9 5.0%           | -         |
| 52 a                           | 0.3       | 0 0.0%         | 0 0.0%           | -         |
| 99                             | 0.03      | 104 25.6%      | 48 26.5%         | -         |
| 101 a                          | 0.03      | 7 1.7%         | 4 2.2%           | -         |
| 105                             | 0.01     | 320 78.8%      | 153 84.5%        | 0.8       |
| 118                             | 0.01     | 405 99.8%      | 181 100.0%       | 4.4       |
| 128                             | 0.01     | 37 9.1%        | 15 8.3%          | -         |
| 138                             | 0.01     | 406 100.0%     | 181 100.0%       | 9.0       |
| 153                             | 0.01     | 406 100.0%     | 181 100.0%       | 21.3      |
| 156                             | 0.01     | 406 100.0%     | 181 100.0%       | 2.9       |
| 170                             | 0.01     | 406 100.0%     | 181 100.0%       | 6.4       |
| 180                             | 0.01     | 406 100.0%     | 181 100.0%       | 1.9       |
| 183                             | 0.01     | 401 98.8%      | 179 98.9%        | 1.5       |
| 187                             | 0.01     | 406 100.0%     | 181 100.0%       | 4.8       |
| **Pesticide analytes**         |           |                |                  |            |
| Alpha-chlordane a               | 0.01     | 2 0.5%         | 0 0.0%           | -         |
| Aldrin a                        | 0.01     | 0 0.0%         | 0 0.0%           | -         |
| β-HCH                           | 0.01     | 392 96.6%      | 179 98.9%        | 5.4       |
| cis-Nonachlor                   | 0.005    | 400 98.5%      | 178 98.3%        | 0.8       |
| Gamma-chlordane a               | 0.005    | 4 1.0%         | 0 0.0%           | -         |
| p,p′-DDE                        | 0.09     | 406 100.0%     | 181 100.0%       | 102.0     |
| p,p′-DDT a                      | 0.05     | 47 11.6%       | 42 23.2%         | -         |
| HCB                             | 0.04     | 406 100.0%     | 181 100.0%       | 9.5       |
| Mirex                           | 0.01     | 322 79.3%      | 133 73.5%        | -         |
| Oxychlordane                    | 0.005    | 396 97.5%      | 172 95.0%        | 4.7       |
| trans-Nonachlor                 | 0.01     | 406 100.0%     | 181 100.0%       | 6.9       |

aExcluded from further analysis due to ≤20% values above the detection limit.
bMedian lipid-adjusted concentration among controls of analytes with >80% of measurements above the limit of detection.
Lipid-adjusted concentrations (µg/kg of lipids) were calculated by dividing the whole-weight measurements of each analyte by the total lipid concentration.\(^4,14\)

Blood sample collection and processing used the same methods for both melanoma cases and NHL controls as previously described. All organochlorine assays were performed at the Centre de Toxicologie in Quebec, Canada; assays for the controls between 2002 and 2005, and for CMM cases in 2008.

### 2.4 Statistical analysis

For those analytes with greater than 80% of samples above the LOD, Spearman rank correlations between the various analytes were examined. Analytes with ≤20% observations above the LOD were excluded from further analyses (aldrin, α-chlordane, γ-chlordane, DDT and PCB congeners nos. 28, 52, 101 and 128). For PCB 99, which only had ~26% of observations above the LOD, concentrations were categorized as detectable or non-detectable. For mirex, in addition to a non-detectable category, the >70% of detectable values were dichotomized based on the distribution among controls. All other analytes were categorized into quartiles according to their distribution among controls. The lowest quartile was used as the reference category. Total PCB level, total dioxin-like PCB level (PCB nos. 118 and 156) and total non-dioxin-like PCB level (PCB nos. 138, 153, 170, 180, 183, and 187) were computed by summing the individual lipid-adjusted serum concentrations of each PCB congener.\(^4,15\) These summary PCB levels were also categorized into quartiles according to distributions among controls.

Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) for risk of CMM in association with each PCB congener and pesticide individually as well as the various summary PCB measures. Tests for trends across the quartiles were calculated by creating a continuous trend variable equal to the median analyte levels within each category for controls for each analyte and aggregate metric. We evaluated potential confounders in our analyses including age, education, hair color, skin color, moles, skin reaction to first sun exposure without sunscreen, skin reaction to repeated sun exposure without sunscreen, total sun exposure during warm months, sun exposure during vacation in warm regions, and recreational sun exposure, the instrument used to evaluate sunlight exposure variables has been well validated and used successfully in a number of previous melanoma studies in populations in multiple countries.\(^16–18\) Age was examined in four categories (20–49, 50–59, 60–69 and 70–79). In separate models for each analyte, if inclusion of a covariate changed the OR estimate for that analyte by more than 5%, the covariate was included in the final statistical model.

All analyses were performed using SPSS for Windows, version 24.0.

### 3 RESULTS

As shown in Figure 1, 39 cases and 43 controls were excluded due to missing samples and incomplete CATI. After further exclusion of participants with missing assay results (1 case and 1 control), non-Caucasian participants (7 cases and 27 controls) and those residing outside the Greater Vancouver Regional District and Capital Regional District (9 cases), 406 cases and 181 controls were included in the analyses (as shown in Tables 1 and 3). For multivariate analyses (Tables 4 and 5), only 375 cases and 171 controls were used due to missing covariate data.

Information on the number of samples measured above the LOD for each analyte is provided in Table 1. Statistically significant correlations between plasma levels of various PCB and pesticide analytes were observed (\(p < .001\)). The strongest correlations were observed between PCB congeners 170, 180, and 187 (\(r > .90\)) and between oxychlordane and trans-Nonachlor (\(r = .939\)) (Table 2).

In general, cases were slightly younger than controls (mean age: 55 vs. 60) and were less educated (bachelor's degree or higher: cases 34.0 vs. 40.9%; Table 3). On average, cases reported a 1.1 pound increase in weight in the time between study entry and 2 years before study entry (i.e., before diagnosis and treatment), while controls reported, on average, a 0.1 pound increase in weight during this time (Table 3). Additionally, compared to controls, a higher proportion of cases had light hair color, fair skin color, and reported many moles. These differences reflect well known differences seen in virtually all studies of melanoma and UV exposure.

Table 4 presents the results of analyses assessing associations of individual and summed PCB congeners with CMM after adjustment for known melanoma risk factors. Statistically significant trends were observed across quartiles for multiple PCB congeners, including PCBs 138, 153, 170, 180, 183 and 187. For example, with PCB 138, compared to the lowest plasma concentration quartile, OR estimates of 2.3 (95% CI, 1.3–4.1) and 2.4 (95% CI, 1.3–4.5) for the second highest and highest quartiles were observed, respectively. Statistically significantly elevated ORs for CMM were also observed across quartile categories of total PCB levels and total non-dioxin-like PCB levels. When comparing the highest to lowest quartile of plasma concentrations, ORs for CMM of 3.1 (95%, CI 1.5–6.3), and 2.6 (1.3–5.3) were observed for total PCBs and total non-dioxin-like PCBs, respectively.

Table 5 provides results of analyses for associations of OC pesticides with CMM risk. Overall, statistically significant trends were observed between CMM and β-HCH, HCB, Mirex, oxychlordane and trans-Nonachlor, with OR estimates for the highest versus lowest quartiles ranging from 1.8 (95% CI 1.0–3.3) for HCB to 4.7 (95% CI 2.3–9.7) for oxychlordane.

### 4 DISCUSSION

In this population-based case–control study, we observed statistically significant increased odds of CMM in association with several individual PCB congeners and OC pesticides after adjustment for known risk factors including constitutional factors and sunlight exposure. As shown in Table 2, plasma levels of several of these analytes were highly correlated, suggesting that observed associations were not necessarily independent of each other.
|          | β-HCH | cis-Nonachlor | p,p’-DDE | HCB   | Oxychlordane | trans-Nonachlor | PCB no. 105 | PCB no. 118 | PCB no. 138 | PCB no. 153 | PCB no. 156 | PCB no. 170 | PCB no. 180 | PCB no. 183 | PCB no. 187 |
|----------|-------|--------------|----------|-------|--------------|----------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| β-HCH    | _     | 0.7          | 0.6      | 0.7   | 0.7          | 0.7            | 0.6         | 0.7         | 0.7         | 0.7         | 0.7         | 0.6         | 0.6         | 0.7         | 0.6         |
| cis-Nonachlor | _     | 0.6          | 0.7      | 0.7   | 0.7          | 0.7            | 0.7         | 0.7         | 0.7         | 0.7         | 0.7         | 0.6         | 0.6         | 0.7         | 0.7         |
| p,p’-DDE | _     | 0.6          | 0.7      | 0.6   | 0.7          | 0.8            | 0.7         | 0.5         | 0.5         | 0.5         | 0.8         | 0.6         | 0.6         | 0.7         | 0.7         |
| HCB      | _     | 0.8          | 0.7      | 0.6   | 0.7          | 0.7            | 0.7         | 0.6         | 0.6         | 0.7         | 0.7         | 0.7         | 0.7         | 0.7         | 0.7         |
| Oxychlordane | _     | 0.9          | 0.6      | 0.7   | 0.7          | 0.7            | 0.8         | 0.8         | 0.7         | 0.7         | 0.7         | 0.7         | 0.7         | 0.7         | 0.7         |
| trans-Nonachlor | _     | 0.6          | 0.7      | 0.7   | 0.7          | 0.7            | 0.7         | 0.7         | 0.7         | 0.7         | 0.7         | 0.7         | 0.7         | 0.7         | 0.7         |
| PCB no. 105 | _     | _            | _        | _     | _            | 0.9            | 0.9         | 0.5         | 0.5         | 0.5         | 0.6         | 0.5         | 0.6         | 0.5         | 0.5         |
| PCB no. 118 | _     | _            | _        | _     | _            | 0.8            | 0.8         | 0.7         | 0.6         | 0.6         | 0.7         | 0.7         | 0.7         | 0.6         | 0.7         |
| PCB no. 138 | _     | _            | _        | _     | _            | 0.9            | 0.9         | 0.8         | 0.9         | 0.9         | 0.9         | 0.9         | 0.9         | 0.9         | 0.9         |
| PCB no. 153 | _     | _            | _        | _     | _            | 1.0            | 0.9         | 0.8         | 0.9         | 0.9         | 0.9         | 0.9         | 0.9         | 0.9         | 0.9         |
| PCB no. 156 | _     | _            | _        | _     | _            | _              | 0.8         | 0.9         | 0.9         | 0.9         | 0.9         | 0.9         | 0.9         | 0.9         | 0.9         |
| PCB no. 170 | _     | _            | _        | _     | _            | _              | _           | _           | _           | _           | _           | _           | _           | _           | _           |
| PCB no. 180 | _     | _            | _        | _     | _            | _              | _           | _           | _           | _           | _           | _           | _           | _           | _           |
| PCB no. 183 | _     | _            | _        | _     | _            | _              | _           | _           | _           | _           | _           | _           | _           | _           | _           |
| PCB no. 187 | _     | _            | _        | _     | _            | _              | _           | _           | _           | _           | _           | _           | _           | _           | _           |
| Characteristics                              | Case N = 406 |          | Control N = 181 |          |
|---------------------------------------------|--------------|----------|-----------------|----------|
| Mean age at diagnosis (SD)                  | 55 (13)      | 60 (12)  | 31              | 49       |
| Mean age at entry in study (SD)             | 58 (13)      | 60 (12)  | 31              | 49       |
| Age group                                   |              |          |                 |          |
| 20–49                                       | 129          | 31.8%    | 110             | 27.1%    |
| 50–59                                       | 110          | 27.1%    | 49              | 27.1%    |
| 60–69                                       | 111          | 27.3%    | 65              | 35.9%    |
| 70–79                                       | 56           | 13.8%    | 36              | 19.9%    |
| Mean weight (lbs) at entry in study (SD)    | 155 (32)     | 151 (28) | 150             | 74       |
| Mean weight (lbs) 2 years before study entry (SD) | 154 (32)     | 150 (27) | 150             | 74       |
| Education                                   |              |          |                 |          |
| Lower than or completed secondary           | 153          | 37.7%    | 59              | 32.6%    |
| Trade or College certificate                | 115          | 28.3%    | 48              | 26.5%    |
| Bachelor’s degree or higher                 | 138          | 34.0%    | 74              | 40.9%    |
| Eye color                                   |              |          |                 |          |
| Dark                                        | 64           | 15.8%    | 39              | 21.5%    |
| Light                                       | 342          | 84.2%    | 142             | 78.5%    |
| Natural hair color                          |              |          |                 |          |
| Dark                                        | 122          | 30.0%    | 78              | 43.1%    |
| Light                                       | 284          | 70.0%    | 103             | 56.9%    |
| Skin color                                  |              |          |                 |          |
| Dark                                        | 76           | 18.7%    | 59              | 32.6%    |
| Fair                                        | 328          | 80.8%    | 122             | 67.4%    |
| Missing                                     | 2            | 0.5%     | 0               | 0        |
| Degree of freckling                         |              |          |                 |          |
| None                                        | 175          | 43.1%    | 91              | 50.3%    |
| Few                                         | 139          | 34.2%    | 56              | 30.9%    |
| Many                                        | 92           | 22.7%    | 33              | 18.2%    |
| Missing                                     | 0            | 0        | 1               | 0.6%     |
| Moles                                       |              |          |                 |          |
| None                                        | 97           | 23.9%    | 59              | 32.6%    |
| Few                                         | 230          | 56.7%    | 101             | 55.8%    |
| Many                                        | 79           | 19.5%    | 20              | 11.0%    |
| Missing                                     | 0            | 0        | 1               | 0.6%     |
| Employment status                           |              |          |                 |          |
| Full time                                   | 163          | 40.1%    | 59              | 32.6%    |
| Part-time                                   | 62           | 15.3%    | 27              | 14.9%    |
| Others                                      | 181          | 44.6%    | 95              | 52.5%    |
| Marital Status                              |              |          |                 |          |
| Married                                     | 286          | 70.4%    | 119             | 65.7%    |
| Single/divorced/widowed                     | 120          | 29.6%    | 61              | 33.7%    |
| Missing                                     | 0            | 0        | 1               | 0.6%     |
| Lifetime number of sunburns                 |              |          |                 |          |
| <=5                                         | 120          | 29.6%    | 61              | 33.7%    |
| >5                                          | 271          | 66.7%    | 120             | 66.3%    |
| Missing                                     | 15           | 3.7%     | 0               | 0        |
Our findings are consistent with data reported in our preliminary case-control study. Median concentrations of most analytes were slightly lower than in the previous study. This is consistent with previously published observations of declining POP concentrations over time. Also, in the current study, the population was restricted to females. In general, only a few studies previously assessed sex-stratified associations of PCBs and melanoma, and no significant sex differences were observed. No studies evaluating sex stratified associations between OC pesticides and CMM were identified.

In a recently conducted prospective study among Swedish women, exposure to dietary PCBs (based on food frequency questionnaire) was associated with a four-fold increased risk of malignant melanoma. In contrast, recently conducted meta-analyses do not
## TABLE 4  Association between summed and individual PCB congeners with CMM

| PCB congeners | Quartiles (μg/kg of lipids) | Cases N = 375<sup>a</sup> | Controls N = 171<sup>a</sup> | OR | 95% CI | p-Trend |
|---------------|-----------------------------|--------------------------|-----------------------------|----|--------|---------|
| PCB no. 99<sup>b</sup> | Not detected                | 280 74.7%                | 130 73.4%                   | 1.0 | 0.8    | 1.9     |
|               | 1.7–107.9                   | 95  25.3%                | 47  26.6%                   | 1.3 | 0.8    | 1.9     |
| PCB no. 105<sup>c</sup> | <0.5                        | 125 33.3%                | 45  25.4%                   | 1.0 | 0.9    | 1.7     |
|               | 0.5 to <0.8                  | 92  24.5%                | 45  25.4%                   | 0.9 | 0.5    | 1.5     |
|               | 0.8 to <1.2                  | 84  22.4%                | 44  24.9%                   | 1.1 | 0.6    | 1.9     |
|               | ≥1.2                        | 74  19.7%                | 43  24.3%                   | 0.9 | 0.5    | 1.8     |
| PCB no. 118<sup>d</sup> | <2.5                        | 105 28.0%                | 45  25.4%                   | 1.0 | 0.8    | 1.9     |
|               | 2.5 to <4.4                  | 113 30.1%                | 45  25.4%                   | 1.7 | 0.9    | 3.0     |
|               | 4.4 to <6.6                  | 87  23.2%                | 43  24.3%                   | 1.7 | 0.9    | 3.0     |
|               | ≥6.6                        | 70  18.7%                | 44  24.9%                   | 1.7 | 0.9    | 3.3     |
| PCB no. 138<sup>e</sup> | <5.1                        | 94  25.1%                | 45  25.4%                   | 1.0 | 0.9    | 2.9     |
|               | 5.1 to <9                    | 95  25.3%                | 43  24.3%                   | 1.7 | 0.9    | 2.9     |
|               | 9 to <13.5                   | 99  26.4%                | 45  25.4%                   | 2.3 | 1.3    | 4.1     |
|               | ≥13.5                       | 87  23.2%                | 44  24.9%                   | 2.4 | 1.3    | 4.5     |
| PCB no. 153<sup>f</sup> | <11.8                       | 88  23.5%                | 44  24.9%                   | 1.0 | 0.9    | 2.9     |
|               | 11.8 to <21.3                | 125 33.3%                | 44  24.9%                   | 2.6 | 1.5    | 4.6     |
|               | 21.3 to <31                  | 85  22.7%                | 45  25.4%                   | 2.5 | 1.3    | 4.7     |
|               | ≥31                         | 77  20.5%                | 44  24.9%                   | 2.7 | 1.4    | 5.1     |
| PCB no. 156<sup>g</sup> | <1.8                        | 103 27.5%                | 44  24.9%                   | 1.0 | 0.9    | 2.9     |
|               | 1.8 to <2.9                  | 102 27.2%                | 45  25.4%                   | 1.5 | 0.8    | 2.7     |
|               | 2.9 to <4.5                  | 96  25.6%                | 45  25.4%                   | 2.2 | 1.2    | 4.2     |
|               | ≥4.5                        | 74  19.7%                | 43  24.3%                   | 1.9 | 0.9    | 3.8     |
| PCB no. 170<sup>h</sup> | <3.9                        | 108 28.8%                | 44  24.9%                   | 1.0 | 0.9    | 2.9     |
|               | 3.9 to <6.4                  | 109 29.1%                | 44  24.9%                   | 1.9 | 1.0    | 3.6     |
|               | 6.4 to <9.2                  | 65  17.3%                | 44  24.9%                   | 1.3 | 0.7    | 2.6     |
|               | ≥9.2                        | 93  24.8%                | 45  25.4%                   | 2.5 | 1.2    | 4.9     |
| PCB no. 180<sup>i</sup> | <12                         | 109 29.1%                | 44  24.9%                   | 1.0 | 0.9    | 2.9     |
|               | 12 to <19                    | 103 27.5%                | 44  24.9%                   | 1.9 | 1.0    | 3.6     |
|               | 19 to <29.5                  | 72  19.2%                | 44  24.9%                   | 1.7 | 0.9    | 3.2     |
|               | ≥29.5                       | 91  24.3%                | 45  25.4%                   | 2.4 | 1.2    | 4.9     |
| PCB no. 183<sup>j</sup> | <0.8                        | 95  25.3%                | 45  25.4%                   | 1.0 | 0.9    | 2.9     |
|               | 0.8 to <1.5                  | 113 30.1%                | 43  24.3%                   | 1.9 | 1.1    | 3.3     |
|               | 1.5 to <2.0                  | 68  18.1%                | 44  24.9%                   | 1.4 | 0.8    | 2.7     |
|               | ≥2.0                        | 99  26.4%                | 45  25.4%                   | 2.5 | 1.3    | 4.6     |
| PCB no. 187<sup>k</sup> | <3.1                        | 106 28.3%                | 43  24.3%                   | 1.0 | 0.9    | 2.9     |
|               | 3.1 to <4.8                  | 97  25.9%                | 46  26.0%                   | 1.5 | 0.8    | 2.9     |
|               | 4.8 to <7.6                  | 83  22.1%                | 43  24.3%                   | 2.1 | 1.1    | 4.1     |
|               | ≥7.6                        | 89  23.7%                | 45  25.4%                   | 2.5 | 1.2    | 5.1     |
| Total PCB summed<sup>l</sup> | <43.6                       | 93  24.8%                | 44  24.9%                   | 1.0 | 0.9    | 2.9     |
|               | 43.6 to <73.7                | 109 29.1%                | 44  24.9%                   | 2.5 | 1.3    | 4.6     |
|               | 73.7 to <113.4               | 89  23.7%                | 44  24.9%                   | 2.8 | 1.4    | 5.5     |
|               | ≥113.4                      | 84  22.4%                | 45  25.4%                   | 3.1 | 1.5    | 6.3     |
| Dioxin-like PCBs<sup>m</sup> | <4.75                       | 100 26.7%                | 45  25.4%                   | 1.0 | 0.9    | 2.9     |
While the studies included in the meta-analyses were (Continued)

Though focused on early life exposures, a recent study found PCBs and OC pesticides to drive sex-specific changes in DNA methylation. The large case group and highly detailed covariate data, particularly related to sun susceptibility and sun exposure, are major strengths of this study. Limitations include the use of post-diagnostic blood samples, in which OC levels may have been impacted by the occurrence of cancer or its treatment. For example, it is known that cancer development and/or its treatment weight loss may lead to increased blood levels of OCs, leading to potential reverse causation.

In addition to chronic inflammation and immunosuppressive effects, it has been shown that PCBs can induce carcinogenesis through prolonged impact on cell receptors (e.g., aryl hydrocarbon receptor [AhR]) leading to cell proliferation, and deregulation of the endocrine system. While oxidative stress and chronic inflammation have been speculated as mechanisms by which pesticides may increase cancer risk, an actual mechanism has not been identified. PCBs and OC pesticides may also induce carcinogenesis through epigenetic mechanisms. Multiple studies have reported significant associations between DNA methylation and exposure to PCBs and OC pesticides.

### TABLE 4 (Continued)

| PCB congeners | Quartiles (μg/kg of lipids) | Cases N = 375<sup>a</sup> | Controls N = 171<sup>a</sup> | OR  | 95% CI | p-Trend |
|--------------|-----------------------------|---------------------------|-----------------------------|-----|--------|---------|
|              | N  | %     | N  | %     |       |         |         |
| 4.75 to <8.5 | 122 | 32.5% | 44 | 24.9% | 1.9   | 1.1     | 3.4     |
| 8.5 to <11.9 | 71  | 18.9% | 44 | 24.9% | 1.4   | 0.8     | 2.7     |
| ≥11.9        | 82  | 21.9% | 44 | 24.9% | 2.1   | 1.1     | 4.1     |
| Non-Dioxin-like PCBs<sup>b</sup> | | | | | | |
| <39.3        | 99  | 26.4% | 44 | 24.9% | 1.0   |        | 0.02    |
| 39.3 to <65.3| 102 | 27.2% | 44 | 24.9% | 2.0   | 1.1     | 3.6     |
| 65.3 to <101.9| 91  | 24.3% | 44 | 24.9% | 2.5   | 1.3     | 4.8     |
| ≥101.9       | 83  | 22.1% | 45 | 25.4% | 2.6   | 1.3     | 5.3     |

<sup>a</sup>Total number of cases and controls included in the analysis after excluding individuals with missing covariates.

<sup>b</sup>Adjusted for age.

<sup>c</sup>Adjusted for age, education, hair color, skin color, moles, and recreational sun exposure.

<sup>d</sup>Adjusted for age, education, hair color, skin color, moles, sunburn, skin reaction to first exposure to sun without sunscreen, skin reaction to repeated sun exposure without sunscreen, total sun exposure during warm months, sun exposure during vacation in warm regions, and recreational sun exposure.

<sup>e</sup>Adjusted for age, education, hair color, skin color, moles, skin reaction to repeated sun exposure without sunscreen, and total sun exposure during warm months.

<sup>f</sup>Adjusted for age, education, hair color, skin color, moles, sunburn, skin reaction to repeated sun exposure without sunscreen, and sun exposure during vacation in warm regions.

<sup>g</sup>Adjusted for age, education, moles, skin reaction to first time sun exposure without sunscreen, skin reaction to repeated sun exposure without sunscreen, and recreational sun exposure.

<sup>h</sup>Adjusted for age, education, moles, skin reaction to first sun exposure without sunscreen, skin reaction to repeated sun exposure without sunscreen, and recreational sun exposure.

<sup>i</sup>Adjusted for age, education, moles, sunburn, skin reaction to repeated sun exposure without sunscreen, and total sun exposure during warm months.

<sup>j</sup>Adjusted for age, education, moles, skin reaction to repeated sun exposure without sunscreen, total sun exposure during warm months, sun exposure during vacation in warm region, and recreational sun exposure.

<sup>k</sup>Adjusted for age, education, moles, skin reaction to repeated sun exposure, sun exposure during vacation in warm region, and recreational sun exposure.

<sup>l</sup>Adjusted for age, education, moles, skin reaction to repeated sun exposure, sun exposure during vacation in warm region, and recreational sun exposure.

<sup>m</sup>Adjusted for age, education, moles, skin reaction to repeated sun exposure, sun exposure during vacation in warm region, and recreational sun exposure.

<sup>n</sup>Adjusted for age, education, moles, skin reaction to repeated sun exposure, sun exposure during vacation in warm region, and recreational sun exposure.

<sup,o</sup>Adjusted for age.
| Pesticide analytes | Quartiles (µg/kg of lipids) | Cases<sup>a</sup> N = 375 | Controls<sup>a</sup> N = 171 | OR  | 95% CI | p-Trend |
|-------------------|-----------------------------|-----------------------------|-----------------------------|-----|-------|---------|
|                   |                              | N  | %     | N  | %     |        |       |
| β-HCH<sup>b</sup> | <3.6                         | 90 | 24.0% | 45 | 25.4% | 1.0    | 0.02  |
|                   | 3.6 to <5.4                  | 93 | 24.8% | 45 | 25.4% | 1.3    | 0.7   | 2.3   |
|                   | 5.4 to <9.7                  | 112| 29.9% | 44 | 24.9% | 2.1    | 1.2   | 3.7   |
|                   | ≥9.7                         | 80 | 21.3% | 43 | 24.3% | 2.3    | 1.2   | 4.4   |
| cis-Nonachlor<sup>c</sup> | <0.5                       | 94 | 25.1% | 45 | 25.4% | 1.0    | 0.09  |
|                   | 0.5 to <0.8                  | 116| 30.9% | 45 | 25.4% | 2.1    | 1.2   | 3.7   |
|                   | 0.8 to <1.3                  | 81 | 21.6% | 43 | 24.3% | 1.8    | 0.9   | 3.2   |
|                   | ≥1.3                         | 84 | 22.4% | 44 | 24.9% | 2.2    | 1.1   | 4.2   |
| DDE<sup>d</sup>   | <55                          | 112| 29.9% | 45 | 25.4% | 1.0    | 0.2   |
|                   | 55 to <102                   | 99 | 26.4% | 43 | 24.3% | 1.3    | 0.8   | 2.2   |
|                   | 102 to <170                  | 74 | 19.7% | 45 | 25.4% | 1.1    | 0.6   | 1.9   |
|                   | ≥170                         | 90 | 24.0% | 44 | 24.9% | 1.5    | 0.9   | 2.3   |
| HCB<sup>e</sup>   | <7.7                         | 116| 30.9% | 45 | 25.4% | 1.0    | 0.02  |
|                   | 7.7 to <9.5                  | 78 | 20.8% | 44 | 24.9% | 0.9    | 0.5   | 1.6   |
|                   | 9.5 to <11.6                 | 83 | 22.1% | 45 | 25.4% | 1.3    | 0.8   | 2.3   |
|                   | ≥11.6                        | 98 | 26.1% | 43 | 24.3% | 1.8    | 1.0   | 3.3   |
| Mirex<sup>f</sup> | Not detected                 | 76 | 20.3% | 48 | 27.1% | 1.0    | 0.03  |
|                   | 0.36 to <1.56                | 172| 45.9% | 64 | 36.2% | 2.3    | 1.4   | 3.8   |
|                   | 1.56 to <32.69               | 127| 33.9% | 65 | 36.7% | 1.9    | 1.1   | 3.3   |
| Oxychlordane<sup>g</sup> | <2.9                      | 81 | 21.6% | 45 | 25.4% | 1.0    | <.001 |
|                   | 2.9 to <4.7                  | 105| 28.0% | 44 | 24.9% | 2.2    | 1.2   | 4.1   |
|                   | 4.7 to <6.8                  | 88 | 23.5% | 45 | 25.4% | 2.5    | 1.3   | 4.8   |
|                   | ≥6.8                         | 101| 26.9% | 43 | 24.3% | 4.7    | 2.3   | 9.7   |
| trans-Nonachlor<sup>h</sup> | <4.5                    | 94 | 25.1% | 45 | 25.4% | 1.0    | <.001 |
|                   | 4.6 to <6.9                  | 90 | 24.0% | 45 | 25.4% | 1.4    | 0.8   | 2.5   |
|                   | 6.9 to <9.9                  | 76 | 20.3% | 44 | 24.9% | 1.7    | 0.9   | 3.2   |
|                   | ≥9.9                         | 115| 30.7% | 43 | 24.3% | 4.3    | 2.1   | 8.5   |

<sup>a</sup>Total number of cases and controls included in the analysis after excluding individuals with missing covariates.
<sup>b</sup>Adjusted for age, education, hair color, skin color, moles, skin reaction to repeated sun exposure without sunscreen, total sun exposure during vacation in warm region, and recreational sun exposure.
<sup>c</sup>Adjusted for age, education, freckling, skin reaction to first sun exposure without sunscreen, sun skin reaction to repeated sun exposure without sunscreen, total sun exposure during warm months, and recreational sun exposure.
<sup>d</sup>Adjusted for age, education, hair color, moles, and total sun exposure during vacation in warm region.
<sup>e</sup>Adjusted for age, education, skin color, and skin reaction to repeated sun exposure without sunscreen.
<sup>f</sup>Adjusted for age, skin color, and recreational sun exposure.
<sup>g</sup>Adjusted for age, education, skin color, moles, marital status, skin reaction to repeated sun exposure, and recreational sun exposure.
<sup>h</sup>Adjusted for age, hair color, moles, skin reaction to repeated sun exposure without sunscreen, total sun exposure during warm months, total sun exposure during vacation in warm region, recreational sun exposure.
has been attributed to an increase in unlisted phone numbers, cell phone usage and screening of calls due to widespread availability of caller identification.\textsuperscript{32,33} While an inadequately representative control population may bias risk estimates,\textsuperscript{34} our findings were consistent with the preliminary study which included a larger number of controls (n = 309)\textsuperscript{3} and, in exploratory analyses, associations with known melanoma risk factors were consistent with those previously reported (results not shown). For example, as compared to having a dark skin color, an OR of 2.0 (95% CI 1.3–3.0) for CMM among those with fair skin was observed in our study. This is comparable to the association reported for fair compared to dark skin in a previously conducted meta-analysis (OR = 1.89; 95% CI, 1.49–2.39).\textsuperscript{35} These findings help reduce concerns about any biases resulting from our control group.

In conclusion, in this study we demonstrated significant associations between various PCB and OC pesticides with CMM risk. Given the highly correlated nature of exposure to PCB and OC analytes, sophisticated analyses that take into account complex mixtures should be considered in future studies.

ACKNOWLEDGMENT

The study was supported by research grant from the Canadian Institutes of Health Research (CIHR) Operating grant MOP-102613.

CONFLICT OF INTEREST

The authors declare there is no conflict of interest.

AUTHOR CONTRIBUTIONS

Formal Analysis, Validation, Visualization, Writing & Original Draft, Writing–Review and Editing, M.D.; Formal Analysis, Validation, Writing–Review and Editing, P.B.; Formal Analysis, Resources, Writing–Review and Editing, E.G.; Data Curation, Formal Analysis, Investigation, Software, Writing–Review and Editing, Z.A.; Resources, Writing–Review and Editing, C.C.; Conceptualization, Funding Acquisition, Methodology, Validation, Writing–Review and Editing, R.G.; Conceptualization, Methodology, Validation, Writing–Review and Editing, J.J.S.; Data Curation, Funding Acquisition, Investigation, Project Administration, Resources, Supervision, Validation, Writing–Review and Editing, T.K.L.

ETHICAL STATEMENT

Ethics was approved by UBC Clinical REB H10-02669. All participants signed an informed consent.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID

Maryam Darvishian \( \text{https://orcid.org/0000-0002-2238-0564} \)

REFERENCES

1. Canadian Cancer Statistics Advisory Committee. Canadian cancer statistics 2019. Toronto, ON: Canadian Cancer Society; 2019.
2. Woods RR, Cопhes MJ, Coldman AJ. Cancer incidence in British Columbia expected to grow by 57% from 2012 to 2030. B C Med J. 2015;57:190-196.
3. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41:45–60.
4. Gallagher RP, Macarthur AC, Lee TK, et al. Plasma levels of polychlorinated biphenyls and risk of cutaneous malignant melanoma: a preliminary study. Int J Cancer. 2011;128:1872-1880.
5. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, International Agency for Research on Cancer, Lyon, France (2016) (polychlorinated and polybrominated biphenyls); 2016.
6. Cao JJ, Fan TQ, Li WH, Xiao S. Association study between plasma levels of polychlorinated biphenyls and risk of cutaneous malignant melanoma. Environ Int. 2019;126:298-301.
7. Boffetta P, Catalani S, Tomasi C, Pira E, Apostoli P. Occupational exposure to polychlorinated biphenyls and risk of cutaneous melanoma: a meta-analysis. Eur J Cancer Prev. 2018;27:62-69.
8. Zani C, Ceretti E, Covolo L, Donato F. Do polychlorinated biphenyls cause cancer? A systematic review and meta-analysis of epidemiological studies on risk of cutaneous melanoma and non-Hodgkin lymphoma. Chemosphere. 2017;183:97-106.
9. Purdue MP, Hoppin JA, Blair A, Dosemeci M, Alavanja MC. Occupational exposure to organochlorine insecticides and cancer incidence in the agricultural health study. Int J Cancer. 2007;120:642-649.
10. Dennis LK, Lynch CF, Sandler DP, Alavanja MC. Pesticide use and cutaneous melanoma in pesticide applicators in the agricultural health study. Environ Health Perspect. 2010;118:812-817.
11. Spinelli JJ, Ng CH, Weber JP, et al. Organochlorines and risk of non-Hodgkin lymphoma. Int J Cancer. 2007;121:2767-2775.
12. Fisher M, Arbuckle TE, Liang CL, et al. Concentrations of persistent organic pollutants in maternal and cord blood from the maternal-infant research on environmental chemicals (MIREC) cohort study. Environ Health. 2016;15:59.
13. Hornung R, Reed L. Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg. 1990;5:46-51.
14. Akins JR, Waldrep K, Bemert JT. The estimation of Total serum-lipids by a completely enzymatic summation method. Clin Chim Acta. 1989;194:219-226.
15. Maysich KB, Mendola P, Schisterman EF, et al. An evaluation of proposed frameworks for grouping polychlorinated biphenyl (PCB) congeners into meaningful analytic units. Am J Ind Med. 1999;35:223-231.
16. English DR, Armstrong BK, Kricker A. Reproducibility of reported measurements of sun exposure in a case-control study. Cancer Epidemiol Biomarkers Prev. 1998;7:857-863.
17. Kricker A, Vajdic CM, Armstrong BK. Reliability and validity of a telephone questionnaire for estimating lifetime personal sun exposure in epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2005;14:2427-2432.
18. Kricker A, Armstrong BK, Goumas C, et al. Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes Control. 2007;18:295-304.
19. Näst TH, Berg V, Hanssen L, et al. Time trends of persistent organic pollutants in 30 year olds sampled in 1986, 1994, 2001 and 2007 in northern Norway: measurements, mechanistic modelling and a comparison of study designs. Environ Res. 2019;172:684-692.
20. Helmfrid I, Berglund M, Löfman O, Wingren G. Health effects and exposure to polychlorinated biphenyls (PCBs) and metals in a contaminated community. Environ Int. 2012;44:53-58.
21. Pavuk M, Cerhan JR, Lynch CF, et al. Environmental exposure to PCBs and cancer incidence in eastern Slovakia. Chemosphere. 2004;54:1509-1520.
22. Donat-Vargas C, Berglund M, Glynn A, Wolk A, Äkesson A. Dietary polychlorinated biphenyls, long-chain n-3 polyunsaturated fatty acids and incidence of malignant melanoma. *Eur J Cancer*. 2017;72:137-143.

23. Stanganelli I, De Felici MB, Mandel VD, et al. The association between pesticide use and cutaneous melanoma: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol*. 2020;34:691-708.

24. Hou L, Andreotti G, Baccarelli AA, et al. Lifetime pesticide use and telomere shortening among male pesticide applicators in the agricultural health study. *Environ Health Perspect*. 2013;121:919-924.

25. van den Dungen MW, Murk AJ, Kampman E, et al. Association between DNA methylation profiles in leukocytes and serum levels of persistent organic pollutants in Dutch men. *Environ Epigenet*. 2017;3:dvx001.

26. Lee MH, Cho ER, Lim JE, Jee SH. Association between serum persistent organic pollutants and DNA methylation in Korean adults. *Environ Res*. 2017;158:333-341.

27. Itoh H, Iwasaki M, Kasuga Y, et al. Association between serum organochlorines and global methylation level of leukocyte DNA among Japanese women: a cross-sectional study. *Sci Total Environ*. 2014;490:603-609.

28. Lind L, Penell J, Lutrop K, et al. Global DNA hypermethylation is associated with high serum levels of persistent organic pollutants in an elderly population. *Environ Int*. 2013;59:456-461.

29. Leung YK, Ouyang B, Niu L, et al. Identification of sex-specific DNA methylation changes driven by specific chemicals in cord blood in a Faroese birth cohort. *Epigenetics*. 2018;13:290-300.

30. Baris D, Kwak LW, Rothman N, et al. Blood levels of organochlorines before and after chemotherapy among non-Hodgkin’s lymphoma patients. *Cancer Epidemiol Biomarkers Prev*. 2000;9:193-197.

31. Morton LM, Cahill J, Hartge P. Reporting participation in epidemiologic studies: a survey of practice. *Am J Epidemiol*. 2006;163:197-203.

32. Galea S, Tracy M. Participation rates in epidemiologic studies. *Ann Epidemiol*. 2007;17:643-653.

33. Hartge P. Participation in population studies. *Epidemiology*. 2006;17:252-254.

34. Aigner A, Grittner U, Becher H. Bias due to differential participation in case-control studies and review of available approaches for adjustment. *Plos One*. 2018;13(1):e0191327.

35. Ghiasvand R, Robsahm TE, Green AC, et al. Association of Phenotypic Characteristics and UV radiation exposure with risk of melanoma on different body sites. *JAMA Dermatol*. 2019;155:39-49.

How to cite this article: Darvishian M, Bhatti P, Gaudreau É, et al. Persistent organic pollutants and risk of cutaneous malignant melanoma among women. *Cancer Reports*. 2022;5(8):e1536. doi:10.1002/cnr2.1536